adivo receives EIC Accelerator Grant
Only 99 highly innovative companies across Europe are supported by the European Commission with a total of 627 million Euros to bring promising technologies to market.
News
Resistell presents spectacular study results
The pilot phase of its clinical Performance Evaluation Study was completed with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.
Our CEO in the German Handelsblatt
Great article in the German Handelsblatt about the most active female venture capital investors in Germany and the introduction of our CEO Patrizia Schützenhöfer.
OCCIDENT welcomes Venture Leaders Deeptech
OCCIDENT has hosted the 15 winner startups of the Swiss Venture Leaders Deeptech program by Venturelab to pitch to selected German deep tech investors.
iThera receives EIC Accelerator Grant
The EIC Accelerator Program is Europe’s largest and most selective public funding program for breakthrough innovation projects.
Team Offsite in Berlin
EAT. BERLIN. SLEEP. REPEAT. For 4 days we did just that at this year’s major offsite in Berlin.
We shape our tomorrow
OCCIDENT funds CO-OPERAID’s Talents project, a scholarship program for young people from very poor families in Bangladesh, Cambodia and Laos.
Investment in mk2 Biotechnologies
OCCIDENT invests in industrial biotech for the first time and participates as lead investor in Munich-based startup mk2 Biotechnologies.